Reviewing TG Therapeutics Inc. (TGTX)’s and Prana Biotechnology Limited (NASDAQ:PRAN)’s results

We are comparing TG Therapeutics Inc. (NASDAQ:TGTX) and Prana Biotechnology Limited (NASDAQ:PRAN) on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TG Therapeutics Inc. N/A 3716.69 173.48M -2.08 0.00
Prana Biotechnology Limited N/A 0.00 N/A -0.66 0.00

In table 1 we can see TG Therapeutics Inc. and Prana Biotechnology Limited’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
TG Therapeutics Inc. 0.00% -185% -127.1%
Prana Biotechnology Limited 0.00% -56.4% -49.9%

Volatility and Risk

TG Therapeutics Inc.’s volatility measures that it’s 114.00% more volatile than Standard & Poor’s 500 due to its 2.14 beta. Competitively, Prana Biotechnology Limited’s beta is 1.06 which is 6.00% more volatile than Standard & Poor’s 500.

Liquidity

TG Therapeutics Inc.’s Current Ratio and Quick Ratio are 2.7 and 2.7 respectively. The Current Ratio and Quick Ratio of its competitor Prana Biotechnology Limited are 4.4 and 4.4 respectively. Prana Biotechnology Limited therefore has a better chance of paying off short and long-term obligations compared to TG Therapeutics Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for TG Therapeutics Inc. and Prana Biotechnology Limited.

Sell Ratings Hold Ratings Buy Ratings Rating Score
TG Therapeutics Inc. 0 0 3 3.00
Prana Biotechnology Limited 0 0 0 0.00

TG Therapeutics Inc.’s upside potential currently stands at 127.10% and an $15.67 consensus price target.

Insider & Institutional Ownership

Roughly 66.1% of TG Therapeutics Inc. shares are owned by institutional investors while 3.6% of Prana Biotechnology Limited are owned by institutional investors. TG Therapeutics Inc.’s share owned by insiders are 0.5%. Competitively, Prana Biotechnology Limited has 18.7% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
TG Therapeutics Inc. 37.7% 66.59% 34.45% -45.58% -52.57% 66.59%
Prana Biotechnology Limited 1.82% 5% -5.62% -19.38% -39.57% 31.25%

For the past year TG Therapeutics Inc. was more bullish than Prana Biotechnology Limited.

Summary

On 5 of the 8 factors Prana Biotechnology Limited beats TG Therapeutics Inc.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.

Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of AlzheimerÂ’s: and that is in Phase IIa clinical trials for the treatment of HuntingtonÂ’s diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for ParkinsonÂ’s disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.